Precise execution

MC Services is...

Client News



… an international Corporate Communications and Investor Relations firm providing high-level consultancy with targeted services and support for transaction-oriented assignments throughout Europe and the United States.


read more


MC Services hosted Press Lounge at the BIO-Europe 2016 in Cologne


This fall, Cologne hosted Europe’s largest partnering conference for the global biotechnology industry - BIO-Europe®. The event took place November 7-9 and had over 3,600 attendees from over 60 countries. MC Services was supporting BIO-Europe® as media partner and hosted the new conference Press Lounge: Centrally located in the exhibit hall – in the midst of activities – journalists were able to retreat to a quiet, fully-equipped work station or use the lounge area to conduct interviews or network with industry representatives.

Twitter: #BIOEurope 2016 #PressLounge


MC Services, EBD Group, BIO.NRW and LaBiotech.eu joined forces for BIO-Europe 2016 live blog


MC Services led a joint initiative with EBD Group, BIO.NRW LaBiotech.eu at BIO-Europe to introduce science journalist students from the “Kölner Journalistenschule” and the TU Dortmund to the biosciences industry. The students were invited to BIO-Europe to conduct interviews with participants and report their impressions of the event, as well as highlights from panels, company presentations and discussions. This content is available in a blog, designed for experts and generalists alike, with the aim of connecting the conference with international audiences and relevant local communities.


Please also follow us on Twitter (@MCServicesAG; #BIOEurope 2016)


The blog is available here


MC Services introduces “BIT” - the BIO-Europe® Investor Talks

During the course of the BIO-Europe 2016, MC Services conducted video interviews with some of the most prominent European investors/VCs in the life sciences space to capture their thoughts on current and future trends in the sector, how the investors are addressing these trends and what exit paths they are realistically seeing in Europe.


The interviews are available here

WILEX signs antibody license agreement with Telix Pharmaceuticals Limited


RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections


RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection


MorphoSys Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients with Type 2 Diabetes


RedHill Biopharma Announces YELIVA(R) (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference


Journal of “Cancer Treatment and Research Communications” Publishes Results of Study with Blood Test Epi proColon®


Seqirus and Zambon enter into a partnership for Parkinson’s disease product in Australia and New Zealand


RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management